Literature DB >> 31154502

Comparison of the diagnostic performance of the 2017 ACR TI-RADS guideline to the Kwak guideline in children with thyroid nodules.

Gali Shapira-Zaltsberg1,2, Elka Miller3,4, Claudia Martinez-Rios3,4, Juan Bass4,5, Ellen B Goldbloom4,6, Ken Tang4,7, Lamia Hayawi4,7, Kerri Highmore3,4.   

Abstract

BACKGROUND: The Kwak Thyroid Imaging Reporting and Data System (Kwak-TI-RADS) guideline (2011) and American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) guideline (2017) were developed as ultrasound (US) risk stratification tools for detecting thyroid malignancy in adults.
OBJECTIVE: The purpose of this study was to investigate the inter-rater reliability and diagnostic performance of the ACR TI-RADS guideline in the pediatric population and compare it to the Kwak guideline.
MATERIALS AND METHODS: This retrospective study comprised 75 children who underwent thyroid US at a tertiary-level pediatric hospital. Three pediatric radiologists and one pediatric radiology fellow graded the US findings using the Kwak-TI-RADS and ACR TI-RADS guidelines. We assessed reliability of radiologists' ratings using percentage inter-rater agreement, and intra-class correlation coefficients (ICC2,1). We assessed area-under-the-receiver-operating-characteristic curve (AUROCC) to compare the discriminative diagnostic ability of the Kwak-TI-RADS and ACR TI-RADS scoring systems against histopathology/cytology, or stability on US over a 2-year follow-up period for cases without tissue diagnosis.
RESULTS: The inter-rater agreement was significantly better for the ACR TI-RADS level compared to the Kwak-TI-RADS level (P<0.001) using the percentage pairwise agreement. The ROC curves for assessing the diagnostic performance of the two methods showed no significant difference between the methods. The AUROCCs for the Kwak-TI-RADS and ACR TI-RADS levels were 0.74 (95% confidence interval [CI] 0.67-0.82) and 0.72 (95% CI 0.61-0.82), respectively.
CONCLUSION: Both the Kwak-TI-RADS and ACR TI-RADS guidelines provide moderate malignancy risk stratification for thyroid nodules in the pediatric population, with better inter-rater agreement for the ACR TI-RADS guideline. Further work to adjust the recommendations for pediatric patients is necessary.

Entities:  

Keywords:  Carcinoma; Children; Nodules; Thyroid; Thyroid Imaging Reporting and Data System; Ultrasound

Year:  2019        PMID: 31154502     DOI: 10.1007/s00247-019-04385-6

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  12 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

2.  ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee.

Authors:  Franklin N Tessler; William D Middleton; Edward G Grant; Jenny K Hoang; Lincoln L Berland; Sharlene A Teefey; John J Cronan; Michael D Beland; Terry S Desser; Mary C Frates; Lynwood W Hammers; Ulrike M Hamper; Jill E Langer; Carl C Reading; Leslie M Scoutt; A Thomas Stavros
Journal:  J Am Coll Radiol       Date:  2017-04-02       Impact factor: 5.532

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Utility of adult-based ultrasound malignancy risk stratifications in pediatric thyroid nodules.

Authors:  Claudia Martinez-Rios; Alan Daneman; Lydia Bajno; Danielle C M van der Kaay; Rahim Moineddin; Jonathan D Wasserman
Journal:  Pediatr Radiol       Date:  2017-10-05

Review 5.  Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines.

Authors:  Marguerite T Parisi; Hedieh Eslamy; David Mankoff
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

6.  Ultrasound risk stratification for malignancy using the 2015 American Thyroid Association Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Jennifer E Lim-Dunham; Iclal Erdem Toslak; Khalid Alsabban; Amany Aziz; Brendan Martin; Gokcan Okur; Katherine C Longo
Journal:  Pediatr Radiol       Date:  2017-01-27

7.  Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk.

Authors:  Jin Young Kwak; Kyung Hwa Han; Jung Hyun Yoon; Hee Jung Moon; Eun Ju Son; So Hee Park; Hyun Kyung Jung; Ji Soo Choi; Bo Mi Kim; Eun-Kyung Kim
Journal:  Radiology       Date:  2011-07-19       Impact factor: 11.105

Review 8.  Sonographic Evaluation of Pediatric Thyroid Nodules.

Authors:  Alex C Essenmacher; Peter H Joyce; Simon C Kao; Monica Epelman; Liuska M Pesce; Michael P D'Alessandro; Yutaka Sato; Craig M Johnson; Daniel J Podberesky
Journal:  Radiographics       Date:  2017-10       Impact factor: 5.333

9.  Thyroid Nodules in Pediatric Patients: Sonographic Characteristics and Likelihood of Cancer.

Authors:  Danielle M Richman; Carol B Benson; Peter M Doubilet; Hope E Peters; Stephen A Huang; Elizabeth Asch; Ari J Wassner; Jessica R Smith; Christine E Cherella; Mary C Frates
Journal:  Radiology       Date:  2018-05-01       Impact factor: 11.105

10.  Interrater reliability: the kappa statistic.

Authors:  Mary L McHugh
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.